Orca Bio

Orca Bio is a late-stage biotechnology company based in Menlo Park, California, focused on developing high-precision allogeneic cell therapies.

Founded in 2016, the company aims to replace diseased blood and immune systems in patients with blood cancer, autoimmune diseases, and genetic blood disorders. Orca Bio's mission is to enhance patient outcomes while minimizing risks compared to standard care. The company's core product is its proprietary manufacturing platform, OrcaSort, which isolates and purifies donor stem and immune cells to create tailored therapeutic mixtures. Its lead investigational product, Orca-T, is an allogeneic T-cell immunotherapy designed to treat various hematological malignancies. In clinical trials, Orca-T has shown promising results, significantly improving survival rates without chronic graft-versus-host disease compared to conventional transplants. Orca Bio serves healthcare professionals, hospitals, and clinical treatment centers, providing safer alternatives to traditional stem cell transplants.